PROMACTA (Page 9 of 9)

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 Tablets

  • The 12.5-mg tablets are round, biconvex, white, film-coated tablets debossed with GS MZ1 and 12.5 on one side and are available in bottles of 30: NDC 0078-0684-15
  • The 25-mg tablets are round, biconvex, orange, film-coated tablets debossed with GS NX3 and 25 on one side and are available in bottles of 30: NDC 0078-0685-15
  • The 50-mg tablets are round, biconvex, blue, film-coated tablets debossed with GS UFU and 50 on one side and are available:
    • Bottles of 14 NDC 0078-0686-55
    • Bottles of 30 NDC 0078-0686-15
  • The 75-mg tablets are round, biconvex, pink, film-coated tablets debossed with GS FFS and 75 on one side and are available in bottles of 30: NDC 0078-0687-15

Store at room temperature between 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Dispense in original bottle.

16.2 For Oral Suspension

  • The 12.5-mg for oral suspension is a reddish-brown to yellow powder in unit-dose packets, co-packaged in a kit with a 40-cc reconstitution vessel, a threaded closure with syringe-port capability, and 30 single-use oral dosing syringes.

Each kit (NDC 0078-0972-61) contains 30 packets: NDC 0078-0972-19

  • The 25-mg for oral suspension is a reddish-brown to yellow powder in unit-dose packets, co-packaged in a kit with a 40-cc reconstitution vessel, a threaded closure with syringe-port capability, and 30 single-use oral dosing syringes.

Each kit (NDC 0078-0697-61) contains 30 packets: NDC 0078-0697-19

Store at room temperature between 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Following reconstitution, the product should be administered immediately but may be stored for a maximum period of 30 minutes between 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Throw away (discard) the mixture if not used within 30 minutes.

17 PATIENT COUNSELING INFORMATION

Advise the patient or caregiver to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).

Prior to treatment, patients should fully understand and be informed of the following risks and considerations for PROMACTA:

Risks

Hepatotoxicity

  • Therapy with PROMACTA may be associated with hepatobiliary laboratory abnormalities [see Warnings and Precautions (5.2)].
  • Advise patients with chronic hepatitis C and cirrhosis that they may be at risk for hepatic decompensation when receiving PROMACTA with alfa interferon therapy [see Warnings and Precautions (5.1)].
  • Advise patients that they should report any of the following signs and symptoms of liver problems to their healthcare provider right away [see Warnings and Precautions (5.2)].
    • yellowing of the skin or the whites of the eyes (jaundice)
    • unusual darkening of the urine
    • unusual tiredness
    • right upper stomach area pain
    • confusion
    • swelling of the stomach area (abdomen)

Risk of Bleeding Upon PROMACTA Discontinuation

  • Advise patients that thrombocytopenia and risk of bleeding may reoccur upon discontinuing PROMACTA, particularly if PROMACTA is discontinued while the patient is on anticoagulants or antiplatelet agents. Advise patients that during therapy with PROMACTA, they should continue to avoid situations or medications that may increase the risk for bleeding.

Thrombotic/Thromboembolic Complications

  • Advise patients that too much PROMACTA may result in excessive platelet counts and a risk for thrombotic/thromboembolic complications [see Warnings and Precautions (5.4)].

Cataracts

  • Advise patients to have a baseline ocular examination prior to administration of PROMACTA and be monitored for signs and symptoms of cataracts during therapy [see Warnings and Precautions (5.5)].

Drug Interactions

  • Advise patients to take PROMACTA at least 2 hours before or 4 hours after calcium-rich foods, mineral supplements, and antacids which contain polyvalent cations, such as iron, calcium, aluminum, magnesium, selenium, and zinc [see Dosage and Administration (2.4), Drug Interactions (7.1)].

Lactation

  • Advise women not to breastfeed during treatment with PROMACTA [see Use in Specific Populations (8.2)].

Administration of PROMACTA

  • For patients with persistent or chronic ITP, therapy with PROMACTA is administered to achieve and maintain a platelet count greater than or equal to 50 x 109 /L as necessary to reduce the risk for bleeding [see Indications and Usage (1.1)].
  • For patients with chronic hepatitis C, therapy with PROMACTA is administered to achieve and maintain a platelet count necessary to initiate and maintain antiviral therapy with pegylated interferon and ribavirin [see Indications and Usage (1.2)].
    • Advise patients to take PROMACTA without a meal or with a meal low in calcium (≤ 50 mg) and at least 2 hours before or 4 hours after other medications (e.g., antacids) and calcium-rich foods [see Dosage and Administration (2.4)].
  • Prior to use of the oral suspension, ensure patients or caregivers receive training on proper dosing, preparation, and administration [see Dosage and Administration (2.4)].
  • Inform patients or caregivers how many packets to administer to get the full dose [see Instructions for Use].
  • Inform patients or caregivers to use a new oral dosing syringe to prepare each dose of PROMACTA for oral suspension [see Instructions for Use].

The following are registered trademarks of their respective owners: PEGASYS/Hoffmann-La Roche Inc.; PEGINTRON/Schering Corporation.

Distributed by:
Novartis Pharmaceuticals CorporationEast Hanover, New Jersey 07936

© Novartis

T2021-06

This Medication Guide has been approved by the U.S. Food and Drug Administration Revised: February 2021
MEDICATION GUIDE
PROMACTA® (pro-MAC-ta)(eltrombopag)tablets PROMACTA® (pro-MAC-ta)(eltrombopag)for oral suspension
What is the most important information I should know about PROMACTA? PROMACTA can cause serious side effects, including: Liver problems:
  • If you have chronic hepatitis C virus and take PROMACTA with interferon and ribavirin treatment, PROMACTA may increase your risk of liver problems. If your healthcare provider tells you to stop your treatment with interferon and ribavirin, you will also need to stop taking PROMACTA.
  • PROMACTA may increase your risk of liver problems that may be severe and possibly life threatening. Your healthcare provider will do blood tests to check your liver function before you start taking PROMACTA and during your treatment. Your healthcare provider may stop your treatment with PROMACTA if you have changes in your liver function blood tests.

Tell your healthcare provider right away if you have any of these signs and symptoms of liver problems:

  • yellowing of the skin or the whites of the eyes (jaundice)
  • unusual darkening of the urine
  • unusual tiredness
  • right upper stomach area (abdomen) pain
  • confusion
  • swelling of the stomach area (abdomen)
See “What are the possible side effects of PROMACTA?” for other side effects of PROMACTA.
What is PROMACTA? PROMACTA is a prescription medicine used to treat adults and children 1 year of age and older with low blood platelet counts due to persistent or chronic immune thrombocytopenia (ITP), when other medicines to treat ITP or surgery to remove the spleen have not worked well enough.

PROMACTA is also used to treat people with:

  • low blood platelet counts due to chronic hepatitis C virus (HCV) infection before and during treatment with interferon.
  • severe aplastic anemia (SAA) in combination with other medicines to treat SAA, as the first treatment for adults and children 2 years of age and older.
  • severe aplastic anemia (SAA) when other medicines to treat SAA have not worked well enough.

PROMACTA is used to try to raise platelet counts in order to lower your risk for bleeding.

PROMACTA is not used to make platelet counts normal.

PROMACTA is not for use in people with a pre-cancerous condition called myelodysplastic syndrome (MDS), or in people with low platelet counts caused by certain other medical conditions or diseases.

It is not known if PROMACTA is safe and effective when used with other antiviral medicines to treat chronic hepatitis C.

It is not known if PROMACTA is safe and effective in children:

  • younger than 1 year with ITP
  • with low blood platelet counts due to chronic hepatitis C
  • whose severe aplastic anemia (SAA) has not improved after previous treatments.
  • younger than 2 years when used in combination with other medicines to treat SAA as the first treatment for SAA.
Before you take PROMACTA, tell your healthcare provider about all of your medical conditions, including if you:
  • have liver problems
  • have a precancerous condition called MDS or a blood cancer
  • have or had a blood clot
  • have a history of cataracts
  • have had surgery to remove your spleen (splenectomy)
  • have bleeding problems
  • are of Asian ancestry (such as Chinese, Japanese, Taiwanese, Korean, or Thai). You may need a lower dose of PROMACTA.
  • are pregnant or plan to become pregnant. It is not known if PROMACTA will harm an unborn baby. Tell your healthcare provider if you become pregnant or think you may be pregnant during treatment with PROMACTA.
    • Females who are able to become pregnant, should use effective birth control (contraception) during treatment with PROMACTA and for at least 7 days after stopping treatment with PROMACTA. Talk to your healthcare provider about birth control methods that may be right for you during this time.
  • are breastfeeding or plan to breastfeed. You should not breastfeed during your treatment with PROMACTA. Talk to your healthcare provider about the best way to feed your baby during this time.
  • Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. PROMACTA may affect the way certain medicines work. Certain other medicines may affect the way PROMACTA works.

Especially tell your healthcare provider if you take:

  • certain medicines used to treat high cholesterol, called “statins”
  • a blood thinner medicine

Certain medicines may keep PROMACTA from working correctly. Take PROMACTA at least 2 hours before or 4 hours after taking these products:

  • antacid medicine used to treat stomach ulcers or heartburn
  • multivitamins or products that contain iron, calcium, aluminum, magnesium, selenium, and zinc which may be found in mineral supplements

Ask your healthcare provider if you are not sure if your medicine is one that is listed above.Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine.

How should I take PROMACTA?
  • Take PROMACTA exactly as your healthcare provider tells you to take it. Your healthcare provider will prescribe the dose of PROMACTA tablets or PROMACTA for oral suspension that is right for you.
  • If your healthcare provider prescribes PROMACTA tablets, take PROMACTA tablets whole. Do not split, chew, or crush PROMACTA tablets and do not mix with food or liquids.
  • If your healthcare provider prescribes PROMACTA for oral suspension, see the “Instructions for Use” that comes with your medicine for instructions on how to correctly mix and take a dose of PROMACTA.
  • Use a new single-use oral dosing syringe to prepare each dose of PROMACTA for oral suspension. Do not re-use the oral dosing syringe.
  • Do not stop taking PROMACTA without talking with your healthcare provider first. Do not change your dose or schedule for taking PROMACTA unless your healthcare provider tells you to change it.
  • Take PROMACTA without a meal or with a meal low in calcium (50 mg or less) and at least 2 hours before or 4 hours after eating calcium-rich foods, such as dairy products, calcium-fortified juices, and certain fruits and vegetables.
  • If you miss a dose of PROMACTA, wait and take your next scheduled dose. Do not take more than 1 dose of PROMACTA in 1 day.
  • If you take too much PROMACTA, you may have a higher risk of serious side effects. Call your healthcare provider right away.
  • Your healthcare provider will check your platelet count during your treatment with PROMACTA and change your dose of PROMACTA as needed.
  • Tell your healthcare provider about any bruising or bleeding that happens while you take and after you stop taking PROMACTA.
  • If you have SAA, your healthcare provider may do tests to monitor your bone marrow during treatment with PROMACTA.
What should I avoid while taking PROMACTA? Avoid situations and medicines that may increase your risk of bleeding.
What are the possible side effects of PROMACTA? PROMACTA may cause serious side effects, including:
  • See “What is the most important information I should know about PROMACTA?”
  • Increased risk of worsening of a precancerous blood condition called myelodysplastic syndrome (MDS) to acute myelogenous leukemia (AML). PROMACTA is not for use in people with a precancerous condition called myelodysplastic syndromes (MDS). See “What is PROMACTA?” If you have MDS and receive PROMACTA, you have an increased risk that your MDS condition may worsen and become a blood cancer called AML. If your MDS worsens to become AML, you may have an increased risk of death from AML.
  • High platelet counts and higher risk for blood clots. Your risk of getting a blood clot is increased if your platelet count is too high during treatment with PROMACTA. Your risk of getting a blood clot may also be increased during treatment with PROMACTA if you have normal or low platelet counts. You may have severe problems or die from some forms of blood clots, such as clots that travel to the lungs or that cause heart attacks or strokes. Your healthcare provider will check your blood platelet counts, and change your dose or stop PROMACTA if your platelet counts get too high. Tell your healthcare provider right away if you have signs and symptoms of a blood clot in the leg, such as swelling, pain, or tenderness in your leg. People with chronic liver disease may be at risk for a type of blood clot in the stomach area (abdomen). Tell your healthcare provider right away if you have stomach-area (abdomen) pain, nausea, vomiting, or diarrhea as these may be symptoms of this type of blood clot.
  • New or worsened cataracts (a clouding of the lens in the eye). New or worsened cataracts can happen in people taking PROMACTA. Your healthcare provider will check your eyes before and during your treatment with PROMACTA. Tell your healthcare provider about any changes in your eyesight while taking PROMACTA.

The most common side effects of PROMACTA in adults and children include:

  • low red blood cell count (anemia)
  • nausea
  • fever
  • abnormal liver function tests
  • cough
  • tiredness
  • headache
  • diarrhea
Laboratory tests may show abnormal changes to the cells in your bone marrow.Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of PROMACTA. For more information, ask your healthcare provider or pharmacist.Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store PROMACTA tablets and PROMACTA for oral suspension? Tablets:
  • Store PROMACTA tablets at room temperature between 68°F to 77°F (20°C to 25°C).
  • Keep PROMACTA in the bottle given to you.
For oral suspension:
  • Store PROMACTA for oral suspension at room temperature between 68°F to 77°F (20°C to 25°C).
  • After mixing, PROMACTA should be taken right away but may be stored for no more than 30 minutes between 68°F to 77°F (20°C to 25°C). Throw away (discard) the mixture if not used within 30 minutes.
Keep PROMACTA and all medicines out of the reach of children.
General information about the safe and effective use of PROMACTA Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use PROMACTA for a condition for which it was not prescribed. Do not give PROMACTA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about PROMACTA that is written for health professionals.
What are the ingredients in PROMACTA? Tablets: Active ingredient: eltrombopag olamine Inactive ingredients:
  • Tablet Core: magnesium stearate, mannitol, microcrystalline cellulose, povidone, and sodium starch glycolate.
  • Coating: FD&C Blue No. 2 aluminum lake (50-mg tablet), FD&C Yellow No. 6 aluminum lake (25-mg tablet), hypromellose, Iron Oxide Black and Iron Oxide Red (75-mg tablet), polyethylene glycol 400, polysorbate 80 (12.5-mg tablet), or titanium dioxide.
For oral suspension: Active ingredient: eltrombopag olamine. Inactive ingredients: mannitol, sucralose, and xanthan gum Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936© Novartis For more information about PROMACTA, go to www.PROMACTA.com or call 1-888-669-6682.

T2021-07

INSTRUCTIONS FOR USE

PROMACTA® [pro-MAC-ta]

(eltrombopag)

for oral suspension

Read all the Instructions for Use and follow the steps below to mix and give a dose of PROMACTA for oral suspension.

Important information you need to know before taking PROMACTA for oral suspension:

  • Do not take PROMACTA for oral suspension or give it to someone else until you have been shown how to properly mix and give a dose of PROMACTA for oral suspension. Your healthcare provider or nurse will show you how to mix and give a dose of PROMACTA for oral suspension properly.
  • PROMACTA for oral suspension must be mixed with cool or cold water only. Do not use hot water to prepare the oral suspension.
  • Give the dose of suspension right away after mixing with water. If the medicine is not given within 30 minutes, you will have to mix a new dose. Throw away (discard) the unused mixture into the trash. Do not pour it down the drain.
  • If PROMACTA for oral suspension comes in contact with your skin, wash the skin right away with soap and water. Call your healthcare provider if you have a skin reaction or if you have any questions. If you spill any powder or liquid, follow the clean-up instructions in Step 12.
  • Contact your healthcare provider or pharmacist if you have any questions about how to mix or give PROMACTA to your child, or if you damage or lose any of the supplies in your kit.
  • Do not re-use the oral dosing syringe. Use a new single-use oral dosing syringe to prepare each dose of PROMACTA for oral suspension.
  • After you have used all 30 packets, throw all the remaining supplies (mixing bottle, lid with cap, and oral dosing syringe) away in the trash.

Each PROMACTA for oral suspension kit contains the following supplies:

30 packets of PROMACTA for oral suspension

Promacta-IFU-illustrations-1

1 Reusable mixing bottle with lid and cap

Promacta-IFU-illustrations-2

30 Single-use 20-mL oral dosing syringes (Use a new (single-use) oral dosing syringe to prepare each dose of PROMACTA for oral suspension)

Promacta-IFU-illustrations-3
(click image for full-size original)

You will need the following to give a dose of PROMACTA for oral suspension.

From the kit:

  • prescribed number of packets
  • 1 reusable mixing bottle with lid and cap. Note: Due to its small size, the cap may pose a danger of choking to small children.
  • 1 single-use 20-mL oral dosing syringe (Use a new (single-use) oral dosing syringe to prepare each dose of PROMACTA for oral suspension)

Not included in the kit:

  • 1 clean glass or cup filled with drinking water
  • scissors to cut packet
  • paper towels or disposable cloth
  • disposable gloves (optional)
This Instructions for Use has been approved by the U.S. Food and Drug Administration.Revised: April 2020

How do I prepare a dose of PROMACTA for oral suspension?

Step 1. Make sure that the mixing bottle, cap, lid and oral dosing syringe are dry before use. Remove the lid from the mixing bottle.

  • Prepare a clean, flat work surface.
  • Wash and dry your hands before preparing the medicine.

Step 2. Fill the oral dosing syringe with 20 mL of drinking water from the glass or cup.

  • Start with the plunger pushed all the way into the syringe.
  • Place the tip of the oral dosing syringe all the way into the water and pull back on the plunger to the 20 mL mark on the barrel of the oral dosing syringe.

Note: Use a new (single-use) oral dosing syringe to prepare each dose of PROMACTA for oral suspension.

Figure 1. Promacta-IFU-illustrations-4

Step 3. Place the tip of the oral dosing syringe into the open mixing bottle. Empty water into open mixing bottle by slowly pushing the plunger all the way into the oral dosing syringe.

Figure 2. Promacta-IFU-illustrations-5
Step 4. Take only the prescribed number of packets for one dose out of the kit. You may need to use more than one packet to prepare the entire dose.
12.5 mg packets Dose Number of 12.5 mg Packets Needed 12.5 mg dose 1 packet 25 mg dose 2 packets 50 mg dose 4 packets 75 mg dose 6 packets
25 mg packets Dose Number of 25 mg Packets Needed 12.5 mg dose 1 packet (Note: See Step 9 for instructions on how to give a 12.5-mg dose using a 25-mg packet.) 25 mg dose 1 packet 50 mg dose 2 packets 75 mg dose 3 packets

Step 5. Add the prescribed number of packets to the mixing bottle.

  • Tap the top of each packet to make sure the contents fall to the bottom.
  • Cut off the top of the packet with scissors and empty the entire contents of the packet into the mixing bottle.
  • Make sure not to spill the powder outside the mixing bottle.
Figure 3. Promacta-IFU-illustrations-6

Step 6. Screw the lid tightly onto the mixing bottle. Make sure the cap is pushed onto the lid.

Step 7. Gently and slowly shake the mixing bottle back and forth for at least 20 seconds to mix the water with the powder.

  • To prevent the mixture from foaming, do not shake the mixing bottle hard.
Figure 4. Promacta-IFU-illustrations-7

How should I give a dose of PROMACTA for oral suspension?

Step 8. Make sure the plunger is pushed all the way into the oral dosing syringe. Pull cap off the mixing bottle lid and insert the tip of the oral dosing syringe into the hole in the lid.

Step 9. Transfer the mixture into the oral dosing syringe. The liquid will be dark brown in color.

  • Turn the mixing bottle upside down along with the oral dosing syringe.
  • Pull back the plunger:
12.5-mg packet
o
until all the medicine is in the oral dosing syringe (12.5-mg, 25-mg, 50-mg, or 75-mg dose)
25-mg packet
o
to the 10 mL mark on the oral dosing syringe for a 12.5-mg dose only OR
o
until all the medicine is in the oral dosing syringe (25-mg, 50-mg, or 75-mg dose).
Figure 5.
Promacta-IFU-illustrations-8
(click image for full-size original)

Step 10. Return the mixing bottle to the upright position and remove the oral dosing syringe from the mixing bottle.

Figure 6.
Promacta-IFU-illustrations-9
(click image for full-size original)

Step 11. Giving a dose of PROMACTA for oral suspension to a child.

  • Place the tip of the oral dosing syringe into the inside of the child’s cheek.
  • Slowly push the plunger all the way down to give the entire dose. Make sure the child has time to swallow the medicine.
Figure 7.
Promacta-IFU-illustrations-10
(click image for full-size original)

How should I clean up?

Step 12. Carefully clean up any spill of the powder or suspension with a damp paper towel or disposable cloth.

  • To avoid possibly staining your skin, consider using disposable gloves.
  • Throw away (discard) used paper towel or disposable cloth and gloves in the trash.

Step 13. Clean the mixing supplies.

  • Do not reuse any of the mixture remaining in the mixing bottle.
  • Throw away (discard) any mixture remaining in the mixing bottle in the trash. Do not pour down the drain.
  • Throw away (discard) the used oral dosing syringe. Use a new (single-use) oral dosing syringe to prepare each dose of PROMACTA for oral suspension.
  • Rinse the mixing bottle and lid under running water and air dry. The mixing bottle may become stained from the medicine. This is normal.
  • Wash hands with soap and water.

How should I store PROMACTA for oral suspension?

  • Store PROMACTA for oral suspension at room temperature between 68°F to 77°F (20°C to 25°C).
  • After mixing, PROMACTA should be taken right away but may be stored for no more than 30 minutes between 68°F to 77°F (20°C to 25°C). Throw away (discard) the mixture if not used within 30 minutes.

Keep PROMACTA and all medicines out of the reach of children.

Distributed by:Novartis Pharmaceuticals CorporationEast Hanover, New Jersey 07936

© Novartis

T2020-61

PRINCIPAL DISPLAY PANEL

NDC 0078-0684-15

Rx only

PROMACTA®

(eltrombopag) Tablets

12.5 mg*

*Each tablet contains eltrombopag olamine equivalent to 12.5 mg of eltrombopag free acid.

Dispense with Medication Guide attached or provided separately.

NOVARTIS

30 Tablets

Promacta 12.5mg 30 count label
(click image for full-size original)

PRINCIPAL DISPLAY PANEL

NDC 0078-0685-15

Rx only

PROMACTA®

(eltrombopag) Tablets

25 mg*

*Each tablet contains eltrombopag olamine equivalent to 25 mg of eltrombopag free acid.

Dispense with Medication Guide attached or provided separately.

NOVARTIS

30 Tablets

Promacta 25mg 30 count label
(click image for full-size original)

PRINCIPAL DISPLAY PANEL

NDC 0078-0686-15

Rx only

PROMACTA®

(eltrombopag) Tablets

50 mg*

*Each tablet contains eltrombopag olamine equivalent to 50 mg of eltrombopag free acid.

Dispense with Medication Guide attached or provided separately.

NOVARTIS

30 Tablets

Promacta 50mg 30 count label
(click image for full-size original)

PRINCIPAL DISPLAY PANEL

NDC 0078-0687-15

Rx only

PROMACTA®

(eltrombopag) Tablets

75 mg*

*Each tablet contains eltrombopag olamine equivalent to 75 mg of eltrombopag free acid.

Dispense with Medication Guide attached or provided separately.

NOVARTIS

30 Tablets

Promacta 75mg 30 count label
(click image for full-size original)

PRINCIPAL DISPLAY PANEL

NDC 0078-0972-61

Rx only

PROMACTA®

(eltrombopag) for Oral Suspension

12.5 mg

Dispense with Medication Guide enclosed or provided separately

30 Packets

Novartis

Promacta for Oral Suspension 12.5 mg 30 packets outer carton
(click image for full-size original)

PRINCIPAL DISPLAY PANEL

NDC 0078-0697-61

Rx only

PROMACTA®

(eltrombopag)for Oral Suspension

25 mg

Dispense with Medication Guide enclosed or provided separately.

30 Packets

NOVARTIS

Promacta for Oral Suspension 12.5 mg 30 packets outer carton
(click image for full-size original)
PROMACTA eltrombopag olamine tablet, film coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0078-0684
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
ELTROMBOPAG OLAMINE (ELTROMBOPAG) ELTROMBOPAG 12.5 mg
Inactive Ingredients
Ingredient Name Strength
MAGNESIUM STEARATE
MANNITOL
CELLULOSE, MICROCRYSTALLINE
POVIDONE
SODIUM STARCH GLYCOLATE TYPE A POTATO
HYPROMELLOSES
POLYETHYLENE GLYCOL 400
TITANIUM DIOXIDE
FERRIC OXIDE RED
FERROSOFERRIC OXIDE
Product Characteristics
Color WHITE Score no score
Shape ROUND Size 10mm
Flavor Imprint Code GS;MZ1;125
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0078-0684-15 30 TABLET, FILM COATED in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA022291 08/22/2016
PROMACTA eltrombopag olamine tablet, film coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0078-0685
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
ELTROMBOPAG OLAMINE (ELTROMBOPAG) ELTROMBOPAG 25 mg
Inactive Ingredients
Ingredient Name Strength
MAGNESIUM STEARATE
MANNITOL
CELLULOSE, MICROCRYSTALLINE
POVIDONE
SODIUM STARCH GLYCOLATE TYPE A POTATO
HYPROMELLOSES
POLYETHYLENE GLYCOL 400
TITANIUM DIOXIDE
FERRIC OXIDE RED
FERROSOFERRIC OXIDE
Product Characteristics
Color ORANGE Score no score
Shape ROUND Size 10mm
Flavor Imprint Code GS;NX3;25
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0078-0685-15 30 TABLET, FILM COATED in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA022291 05/24/2016
PROMACTA eltrombopag olamine tablet, film coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0078-0686
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
ELTROMBOPAG OLAMINE (ELTROMBOPAG) ELTROMBOPAG 50 mg
Inactive Ingredients
Ingredient Name Strength
MAGNESIUM STEARATE
MANNITOL
CELLULOSE, MICROCRYSTALLINE
POVIDONE
SODIUM STARCH GLYCOLATE TYPE A POTATO
HYPROMELLOSES
POLYETHYLENE GLYCOL 400
TITANIUM DIOXIDE
FD&C BLUE NO. 2
Product Characteristics
Color BLUE Score no score
Shape ROUND Size 10mm
Flavor Imprint Code GS;UFU;50
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0078-0686-15 30 TABLET, FILM COATED in 1 BOTTLE None
2 NDC:0078-0686-55 14 TABLET, FILM COATED in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA022291 04/07/2016
PROMACTA eltrombopag olamine tablet, film coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0078-0687
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
ELTROMBOPAG OLAMINE (ELTROMBOPAG) ELTROMBOPAG 75 mg
Inactive Ingredients
Ingredient Name Strength
MAGNESIUM STEARATE
MANNITOL
CELLULOSE, MICROCRYSTALLINE
POVIDONE
SODIUM STARCH GLYCOLATE TYPE A POTATO
HYPROMELLOSES
POLYETHYLENE GLYCOL 400
TITANIUM DIOXIDE
FERRIC OXIDE RED
FERROSOFERRIC OXIDE
Product Characteristics
Color PINK Score no score
Shape ROUND Size 10mm
Flavor Imprint Code GS;FFS;75
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0078-0687-15 30 TABLET, FILM COATED in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA022291 04/01/2016
PROMACTA eltrombopag olamine powder, for suspension
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0078-0972
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
ELTROMBOPAG OLAMINE (ELTROMBOPAG) ELTROMBOPAG 12.5 mg
Inactive Ingredients
Ingredient Name Strength
SUCRALOSE
MANNITOL
XANTHAN GUM
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0078-0972-61 1 CARTON in 1 KIT contains a CARTON (0078-0972-23)
1 NDC:0078-0972-23 30 PACKET in 1 CARTON This package is contained within the KIT (0078-0972-61) and contains a PACKET (0078-0972-19)
1 NDC:0078-0972-19 1 POWDER, FOR SUSPENSION in 1 PACKET This package is contained within a CARTON (0078-0972-23) and a KIT (0078-0972-61)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA207027 09/27/2018
PROMACTA eltrombopag olamine powder, for suspension
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0078-0697
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
ELTROMBOPAG OLAMINE (ELTROMBOPAG) ELTROMBOPAG 25 mg
Inactive Ingredients
Ingredient Name Strength
SUCRALOSE
MANNITOL
XANTHAN GUM
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0078-0697-61 1 CARTON in 1 KIT contains a CARTON (0078-0697-23)
1 NDC:0078-0697-23 30 PACKET in 1 CARTON This package is contained within the KIT (0078-0697-61) and contains a PACKET (0078-0697-19)
1 NDC:0078-0697-19 1 POWDER, FOR SUSPENSION in 1 PACKET This package is contained within a CARTON (0078-0697-23) and a KIT (0078-0697-61)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA207027 09/27/2018
Labeler — Novartis Pharmaceuticals Corporation (002147023)

Revised: 04/2021 Novartis Pharmaceuticals Corporation

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2021. All Rights Reserved.